

Making a Cancer Diagnosis: Key Concepts

08/01/18 Expiration Date: 12/01/18

Jointly provided by



and



Intended Audience

Nurse Practitioners, Nurse Midwives and Physician Assistants in acute and primary care roles.

Learning Objectives

Upon completion of this activity, the participant should be able to:

- Identify common symptoms, laboratory abnormalities and radiographic findings associated the diagnosis of breast cancer, colorectal cancer, prostate cancer, and melanoma.
- Describe factors influencing cancer diagnosis such as race, gender, socioeconomic status and geographic location.
- Develop a general understanding of current cancer treatment modalities including surgery, radiation, chemotherapy and immunotherapy.

Statement of Need

It is estimated that approximately 1.7 million new cases of cancer will be diagnosed in the US in 2017, and more than 15 million Americans are living today with a cancer history. Cancer is one of the leading causes of death and disease in the US. Understand the diagnosis and work up of five of the most common cancers: breast cancer, colorectal cancer, lung cancer, prostate cancer and melanoma. Potential barriers to diagnosis will be discussed, as well as what to expect for cancer therapies. The role of the Advanced Practice Provider as an essential member of the multidisciplinary care team making the cancer diagnosis will be highlighted.

Accreditation Statement(s)



In support of improving patient care, this activity has been planned and implemented by Dannemiller and National Nurse Practitioner Symposium. Dannemiller is jointly accredited by the Accreditation Council for Continuing

Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physicians

Dannemiller designates this enduring material for a maximum of 1.5 *AMA PRA Category 1 Credit(s)*[™]. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nurse Practitioners



This activity has been planned and implemented in accordance with the accreditation Standards of the American Association of Nurse Practitioners (AANP) through the joint providership of Dannemiller and

National Nurse Practitioner Symposium. Dannemiller is accredited by the American Association of Nurse Practitioners as an approved provider of nurse practitioner continuing education.

Provider number: 090419. This program is accredited for 1.5 contact hour(s) which includes 0.25 hours of pharmacology.

Nurses

Dannemiller designates this enduring material for 1.5 contact hour(s).

Method of Participation

Participants should first read the objectives and other introductory CME/CE information and then proceed to the educational activity. To receive your contact/CE hours view the presentation video, and complete and pass a 10-question test on the presentation content (80% is considered passing).

Credit is provided through December 1, 2018. No credit will be given after this date. If you attended the 2018 National Nurse Practitioner Symposium, these enduring materials hours are complimentary and separate from the contact/CE hours you received at the live meeting. If you did not attend the 2018 National Nurse Practitioner Symposium, the cost is \$5 per test attempt. If you are not successful in passing a test on first attempt, you may retake the same test after a 24 hour grace period, which allows you time to review the presentation video again.

Faculty

Brianna Hoffner, RN, MSN, AOCNP, ANP-BC; Lead Advanced Practice Provider, Medical Oncology, University of Colorado Hospital; Aurora CO and Assistant Professor, Medical Oncology, School of Medicine, University of Colorado Anschutz Medical Campus; Aurora CO

Johanna Warner, AGNP-C, MSN, OCN; Nurse Practitioner – GI/Phase I Clinical Trial Clinic, Cancer Center, University of Colorado Hospital; Aurora CO

Disclosures

In accordance with the Accreditation Council for Continuing Medical Education (ACCME), Dannemiller requires that any person who is in a position to control the content of a CME/CE activity must disclose all financial relationships they have with a commercial interest.

The following faculty members have no financial relationships with commercial interests: Brianna Hoffner, RN, MSN, AOCNP, ANP-BC and Johanna Warner, AGNP-C, MSN, OCN

Bernard Abrams, MD content reviewer; Jennifer Hodge, Project Manager, Dannemiller; and NNPS coordinating staff have no financial relationships with commercial interests.

To resolve identified/potential conflicts of interest, the educational content was fully reviewed

by a member of the Dannemiller Clinical Content Review Committee who has nothing to disclose. The resulting certified activity was found to provide educational content that is current, evidence based and commercially balanced.

Off-label statement

Off label statement provided: This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by FDA. The opinions expressed in the educational activity are those of the faculty. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings. Further, attendees/participants should appraise the information presented critically and are encouraged to consult appropriate resources for any product or device mentioned in this program.

Disclaimer

The content and views presented in this educational activity are those of the authors and do not necessarily reflect those of Dannemiller or National Nurse Practitioner Symposium. This material is prepared based upon a review of multiple sources of information, but it is not exhaustive of the subject matter. Therefore, healthcare professionals and other individuals should review and consider other publications and materials on the subject